TP53 and cancer: The identification of recurrent activating mutations in the TERT promoter across several types of human cancers, along with the widespread mutations in p53 observed in cancers, may provide some evidence suggesting that the reactivation of telomerase through heightened TERT expression enables cancer cells to bypass the telomere-p53 checkpoint, thereby contributing to cancer progression [46] (Fig. 3).